GlaxoSmithKline has dismissed reports that hundreds of jobs in Ireland are at risk.

Citing an unnamed GSK spokeswoman, the Irish Examiner newspaper reported that a business review of its operations in the whole of the country is underway and quoted sources as saying that signifcant job cuts could happen. The company employs almost 1,400 people in Ireland at facilities in Cork, Dungarvan and Dublin.

However the Irish Independent paper says that a company spokesman has revealed that the aforementioned report is “completely inaccurate” and any measures taken will only affect its manufacturing facility at Currabinny, Cork. The GSK spokesman told the newspaper that the company “recently briefed its workforce that as part of its ongoing restructuring programme, first introduced in 2008, it is undertaking a business review at the Cork site which is expected to be completed by the autumn”.

Meantime, GSK has suffered two setbacks at the hands of the National Institute for Health and Clinical Excellence. The UK cost regulator has issued draft guidance advising against funding for Tyverb (lapatinib), in combination with Roche's Xeloda (capecitabine), as a treatment for an aggressive form of advanced breast cancer and after a preliminary review has ruled against the clotting disorder treatment Revolade (eltrombopag).

NICE believes that the two treatments are too expensive to be paid for by the National Health Service. For full details of the guidances, see today’s UK News.